NEW YORK (GenomeWeb News) – Rosetta Genomics reported after the close of the market Tuesday that its second-quarter net loss rose 62 percent, as well as plans to eventually spin off its new cleantech division.

The Rehovot, Israel-based developer of microRNA-based tests brought in revenues of $14,000 for the three-month period ended June 30, compared to no revenues for the second quarter of 2008. Rosetta noted that revenues it previously reported for Parkway Clinical Laboratories, which it sold for $2.5 million during the quarter, is now recorded under discontinued operations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

The Wall Street Journal looks into the cost of new gene therapies.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
11
Sponsored by
ArcherDX

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.